390 filings
EFFECT
PULM
Pulmatrix Inc
31 May 24
Notice of effectiveness
12:15am
8-K
PULM
Pulmatrix Inc
29 May 24
Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation
8:45am
S-3
PULM
Pulmatrix Inc
Shelf registration
17 May 24
4:06pm
8-K
PULM
Pulmatrix Inc
15 May 24
Regulation FD Disclosure
9:00am
10-Q
2024 Q1
PULM
Pulmatrix Inc
Quarterly report
10 May 24
9:20am
8-K
5el34q88p1 3h1qne
10 May 24
Pulmatrix Announces First Quarter 2024 Financial Results and Provides Corporate Update
9:05am
424B3
094b5z49i
28 Mar 24
Prospectus supplement
9:25am
8-K
5glf673dcm
28 Mar 24
Pulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate Update
9:05am
8-K
arjhit me7tfp2go20hf
13 Mar 24
Departure of Directors or Certain Officers
6:03am
8-K
538kv5t
4 Mar 24
Regulation FD Disclosure
4:06pm
8-K
pjt63itaj1d ykx
8 Jan 24
Entry into a Material Definitive Agreement
9:00am
8-K
pbtj3j a7a3t
9 Nov 23
Pulmatrix Announces Third Quarter 2023 Financial Results and Provides Corporate Update
9:05am
8-K
mxj64
10 Aug 23
Pulmatrix Announces Second Quarter 2023 Financial Results and Provides Corporate Update
9:05am
8-K
x98zgt9
13 Jul 23
Submission of Matters to a Vote of Security Holders
4:05pm
8-K
239zua9w9qrgnjlxulw3
11 Jul 23
Pulmatrix Announces Submission of IND Application to FDA to Initiate a Phase 2 Trial of Investigational Drug PUR3100 to Treat Acute Migraine
9:05am
ARS
5qad n8k0z5t
2 Jun 23
Annual report to shareholders
9:25am